JP2015524055A - ガン患者における抗血管新生療法に対する応答及び該療法後の生存についての予知バイオマーカーとしてのｍｍｐ２ - Google Patents

ガン患者における抗血管新生療法に対する応答及び該療法後の生存についての予知バイオマーカーとしてのｍｍｐ２ Download PDF

Info

Publication number
JP2015524055A
JP2015524055A JP2015513339A JP2015513339A JP2015524055A JP 2015524055 A JP2015524055 A JP 2015524055A JP 2015513339 A JP2015513339 A JP 2015513339A JP 2015513339 A JP2015513339 A JP 2015513339A JP 2015524055 A JP2015524055 A JP 2015524055A
Authority
JP
Japan
Prior art keywords
mmp2
cancer
patients
levels
response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2015513339A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015524055A5 (https=
Inventor
シノ，オリヴィエ
タブレ，エメリン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aix Marseille Universite
Assistance Publique Hopitaux de Marseille APHM
Original Assignee
Aix Marseille Universite
Assistance Publique Hopitaux de Marseille APHM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aix Marseille Universite, Assistance Publique Hopitaux de Marseille APHM filed Critical Aix Marseille Universite
Publication of JP2015524055A publication Critical patent/JP2015524055A/ja
Publication of JP2015524055A5 publication Critical patent/JP2015524055A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7014—(Neo)vascularisation - Angiogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2015513339A 2012-05-23 2013-05-23 ガン患者における抗血管新生療法に対する応答及び該療法後の生存についての予知バイオマーカーとしてのｍｍｐ２ Withdrawn JP2015524055A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305565.9 2012-05-23
EP12305565.9A EP2667193A1 (en) 2012-05-23 2012-05-23 MMP2 as a predictive biomarker of response to antiangiogenic therapy and survival after therapy in cancer patients
PCT/IB2013/054275 WO2013175429A1 (en) 2012-05-23 2013-05-23 Mmp2 as a predictive biomarker of response to antiangiogenic therapy and survival after therapy in cancer patients

Publications (2)

Publication Number Publication Date
JP2015524055A true JP2015524055A (ja) 2015-08-20
JP2015524055A5 JP2015524055A5 (https=) 2016-06-16

Family

ID=48782563

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015513339A Withdrawn JP2015524055A (ja) 2012-05-23 2013-05-23 ガン患者における抗血管新生療法に対する応答及び該療法後の生存についての予知バイオマーカーとしてのｍｍｐ２

Country Status (4)

Country Link
US (1) US20150148248A1 (https=)
EP (2) EP2667193A1 (https=)
JP (1) JP2015524055A (https=)
WO (1) WO2013175429A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021167827A (ja) * 2016-01-25 2021-10-21 サノフイSanofi 血漿バイオマーカーのレベルを測定することによる、がんに罹患していることが疑われる患者のアフリベルセプトによる治療の転帰を予測するための方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013031019A2 (pt) 2011-06-02 2017-03-21 Almac Diagnostics Ltd teste diagnóstico molecular para câncer
MX2015006955A (es) 2012-12-03 2016-01-25 Almac Diagnostics Ltd Prueba de diagnostico molecular para cancer.
GB201409476D0 (en) * 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular subtype for use in prognosis
CN107604074B (zh) * 2017-10-27 2020-06-30 中南大学湘雅医院 胶质瘤预后标志物circ15:101235082|101235577及应用
CN107937532B (zh) * 2017-12-28 2020-06-30 中南大学湘雅医院 胶质瘤诊断标志物hsa_circ_0021827及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
BR112013031019A2 (pt) * 2011-06-02 2017-03-21 Almac Diagnostics Ltd teste diagnóstico molecular para câncer

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021167827A (ja) * 2016-01-25 2021-10-21 サノフイSanofi 血漿バイオマーカーのレベルを測定することによる、がんに罹患していることが疑われる患者のアフリベルセプトによる治療の転帰を予測するための方法
JP7170096B2 (ja) 2016-01-25 2022-11-11 サノフイ 血漿バイオマーカーのレベルを測定することによる、がんに罹患していることが疑われる患者のアフリベルセプトによる治療の転帰を予測するための方法

Also Published As

Publication number Publication date
WO2013175429A1 (en) 2013-11-28
EP2667193A1 (en) 2013-11-27
US20150148248A1 (en) 2015-05-28
EP2852842A1 (en) 2015-04-01

Similar Documents

Publication Publication Date Title
Martins et al. Proinflammatory and anti‐inflammatory cytokines mediated by NF‐κB factor as prognostic markers in mammary tumors
Tabouret et al. Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma
US20180045730A1 (en) Methods for predicting tumor response to targeted therapies
JP2015524055A (ja) ガン患者における抗血管新生療法に対する応答及び該療法後の生存についての予知バイオマーカーとしてのｍｍｐ２
Radhakrishnan et al. Inhibition of rapamycin-induced AKT activation elicits differential antitumor response in head and neck cancers
Farina et al. Relationship between magnetic resonance imaging characteristics and plasmatic levels of MMP2 and MMP9 in patients with recurrent high-grade gliomas treated by Bevacizumab and Irinotecan
US12298307B2 (en) PD-ECGF as biomarker of cancer
JP7564097B2 (ja) ソラフェニブ化合物を含む療法のためのバイオマーカー
JP7122016B2 (ja) グリオーマの予後、遠隔部再発リスク及び浸潤を判定する方法及びキット並びにグリオーマを処置するための医薬組成物
JP6836230B2 (ja) がん又は炎症性疾患患者の予後を予測する方法
US11415584B2 (en) Biomarkers, test method, and test kit for predicting therapeutic effect of anti-VEGFR-2 antibody drug
WO2015161885A1 (en) Hepatocyte growth factor as marker of prognosis in small cell lung cancer (sclc)
US20110165577A1 (en) Selection of colorectal cancer patients for neo-adjuvant and adjuvent systemic anti-cancer treatment
WO2009098656A2 (en) Method for predicting or diagnosing outcome of intracranial tumors in a subject
Gharib et al. Prognostic significance of dipeptidyl peptidase-7 (DPP7) in HPV16-negative head and neck squamous cell carcinoma treated with induction chemoradiotherapy
Kang et al. Active Ratio Test (ART) as a Novel Diagnostic for Ovarian Cancer. Diagnostics 2021, 11, 1048
KR20250033118A (ko) 신장암에서 면역 관문 억제제의 치료 반응성 예측 마커 및 이를 이용한 치료 반응성 예측 방법
CA2978653C (en) Pd-ecgf as biomarker of cancer
Ianza VALIDATION OF PREDICTIVE AND PROGNOSTIC BIOMARKERS AS A GUIDE FOR A PERSONALIZED APPROACH IN SOLID TUMOURS
WO2025121385A1 (ja) Ｔ細胞関連疾患の病態、予後及び治療効果の予測技術
WO2023022200A1 (ja) 免疫チェックポイント阻害剤に対する応答性の予測用バイオマーカー
JP2022529073A (ja) 診断方法
CN103620412A (zh) 作为对表皮生长因子受体治疗剂治疗的响应的预测物的cxcr1
WO2020257461A1 (en) A method for predicting risk of recurrence for early-stage colon cancer by measuring focal adhesion kinase
HK1262691A1 (en) Chromogranin a as a marker for bladder cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160419

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160419

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20160620